Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 10 and older~* Documented diagnosis of HAE, Type I or II~* Executed informed consent~* Presentation for treatment within 8 hours of patient recognition of moderate to severe HAE attack~Exclusion Criteria:~* Receipt of investigational drug or device, other than DX-88, within 30 days of treatment~* Receipt of non-investigational C1-INH (C1 esterase inhibitor) within 7 days of treatment~* Diagnostic of acquired angioedema, estrogen-dependent angioedema or drug induced angioedema~* Pregnancy or breastfeeding~* Patients who have received DX-88 within 7 days of presentation for dosing in the Double-blind Phase

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DX-88 (ecallantide) (Type: EXPERIMENTAL): DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
- Placebo (Type: PLACEBO_COMPARATOR): Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).